2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow MorphoSys AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2023-08-04 | 2025-09-05 |
| Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) MOR00208 (formerly Xmab5574) - Acute Lymphoblastic Leukemia | Phase 2 | Terminated | MorphoSys AG | 22 | 2013-04-01 | 2018-02-22 |
Burkitt Lymphoma (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
tafasitamab (2) · Lenalidomide (1)
United States (2) · Japan (1) · South Korea (1)
Elias Jabbour, MD (1) · Rebecca Klisovic, MD (1) · Wing H. Leung, M.D., PhD (1)